



RECEIVED

FEB 13 2003

TECH CENTER 1600/2000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PATENT

Applicant: P. A. Billing-Medel, *et al.*

Serial No.: 09/092,296

Filed: June 6, 1998

For: REAGENTS AND METHODS
USEFUL FOR DETECTING
DISEASES OF THE LUNG

Examiner: G. Nickol

Group Art Unit: 1642

Attorney Docket No.: 6104.US.P1

Dated: January 29, 2003

Certificate of Mailing under 37 CFR §1.8(a):

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service with sufficient postage as First Class Mail addressed to:

Assistant Commissioner for Patents

Washington, D.C. 20231

Date of Deposit: February 5, 2003

Wanda E. Smith

Wanda E. Smith

#

34
100

2-27-03

DECLARATION OF PAULA N. FRIEDMAN, Ph.D.
UNDER 37 C.F.R. SECTION 1.132

Sir:

1. I am one skilled in the art of cancer diagnostics. I have a Ph.D and M.A. in Molecular Biology from Columbia University. I also have a B.A. in Biology from Dartmouth College.
2. I was a Postdoctoral Fellow in the Laboratory of Dr. Clay Siegall at the Pharmaceutical Research Institute at Bristol-Myers Squibb and an Assistant Pharmacologist, Department of Clinical Immunology & Biol. Therapy at the MD Anderson Cancer Center.
3. I have nine (9) years of research and development experience in the cancer diagnostic industry. Much of my work has involved the discovery and validation of novel cancer markers to improve the accuracy of diagnosing the onset of cancer. In fact, I am a named inventor on several U.S. Patents, all of which are related to the field of cancer diagnostics.
4. I also have authored numerous journal articles relating to cancer pathology, detection and metastasis (See Exhibit A).
5. I am one of the named inventors on the present application.

6. I have read and am familiar with the Office Action dated November 22, 2002 and the utility rejection under 35 U.S.C. Section 101 applied against the present application.

7. The identification of molecular markers to identify diseases in humans is extremely important. Several different categories of markers are known in the art. One such category of markers are those that are genes that are expressed in a tissue-specific manner but can appear in an inappropriate body compartment. The expression of a marker in a tissue or body compartment where their normal occurrence is very low or non-existent indicates that a disease has altered the marker so that has escaped from its host tissue. Examples of markers that fall into this category are prostate specific antigen (PSA) and carcinoembryonic antigen (CEA).

PSA is a member of the human tissue kallikrein gene family. PSA is normally secreted at high levels into the seminal fluid and is present in very low levels in the blood of men with normal prostates. However, in patients with diseases of the prostate, including benign prostatic hyperplasia (BPH) or adenocarcinoma of the prostate, the level of PSA is markedly elevated in the blood and is a strong indication of disease of the prostate.

Similarly, CEA is a normal component of the inner lining of the colon and is present stool and in blood at low levels in people without disease of the colon. However, in disease of the colon, including inflammatory bowel disease and adenocarcinoma of the colon, the concentration of CEA is markedly elevated in the blood plasma or serum of many patients and is an indicator of disease of that tissue (such as colorectal cancer).

8. I have reviewed the data illustrating CEA and PSA tissue specificity generated using the Incyte Lifeseq Gold database. The Incyte Lifeseq Gold database is a very large database of expressed sequence tags (ESTs). This is the database where the inventors of the present application discovered the markers that are the subject of the present application.

9. CEA is a tissue-specific marker that has been shown to be highly expressed in the gastrointestinal (GI) tract. Specifically, 61 out of 148 GI libraries express CEA whereas only 27 out of 1,144 other, non-GI tract libraries express this gene. Therefore, CEA is expressed approximately 17 times more in GI tissue when compared to the rest of the body.

10. Similarly, PSA is a tissue-specific marker that has been shown to be highly expressed in prostate. Specifically, 65 out of 79 prostate libraries (classified as male genitalia) express PSA whereas only 22 out of 1213 other, non-prostate libraries express this gene. Therefore, PSA is expressed approximately 45 times more in prostate when compared to the rest of the body.

11. To those skilled in the art, such as myself, PSA and CEA are well known tumor markers, which indicate cancer of the prostate (PSA) and GI tract (CEA) when the respective gene product is found in the blood sample of a patient.
12. As shown in the instant specification, LS147 is expressed only in lung tissue.
13. Clearly, LS147 is characteristic of a tissue specific marker and able to act as a cancer diagnostic, as evidenced by the specification.
14. Tissue-specific markers such as PSA and CEA are the most diagnostic tools in early oncology detection and are used on a daily basis. Further, the PSA gene product is utilized in screening, prognosis and monitoring prostate cancer patients by oncologists and is recommended that all men over the age of 40 be tested yearly with a PSA assay.
15. Based on the statistics in the Incyte database, LS147 is clearly a lung specific marker and, therefore, its use as a lung cancer marker is unquestionable. Therefore, to one of ordinary skill in the art, such as myself, the presence of LS147 outside of the lung would indicate cancer development of that tissue, just as the presence of CEA and PSA outside of their respective tissues indicates cancer of the colon and prostate, respectively.
16. I hereby declare that all statements made herein are of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that the statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.



Paula N. Friedman, Ph.D

2/5/03

Date



ATTACHMENT I

RECEIVED
FEB 13 2003
TECH CENTER 1600/2300

Publications:

Wang, E.H., **Friedman, P.N.** and Prives, C. 1989. The murine p53 protein blocks replication of SV40 DNA in vitro by inhibiting the initiation functions of SV40 large T antigen. *Cell*, 57, 379-392.

Manfredi, J.J., Wang, E.H., **Friedman, P.N.**, and Prives, C. 1989. Purified SV40 large T antigen in complex with murine p53 does not support SV40 DNA replication in vitro. Implications for the mechanism of transformation by SV40 large T antigen. In *Common Mechanisms of Transformation by Small DNA Tumor Viruses*. Luis P. Villeareal, ed. American Society for Microbiology, 113.

Bischoff, J.R., **Friedman, P.N.**, Marshak, D., Prives, C., and Beach, D. 1990. The p53 protein is phosphorylated by cyclin A-cdc2 as well as cyclin B-cdc2. *PNAS*, 87, 4766-4770.

Friedman, P.N., Kern, S.E., Vogelstein, B., and Prives, C. 1990. Wild-type, but not mutant, human p53 proteins inhibit the replication activities of simian virus 40 large tumor antigen. *PNAS*, 87, 9275-9279.

Kern, S.E., Kinzler, K.W., Baker, S.J., Nigro, J.M., Rotter, V., Levine, A.J., **Friedman, P.N.**, Prives, C. and Vogelstein, B. 1991. Mutant p53 proteins bind DNA abnormally in vitro. *Oncogene*, 6, 131-136.

Bargonetti, J., **Friedman, P.N.**, Kern, S.E., Vogelstein, B., and Prives, C. 1991. Wild-type but not mutant p53 immunopurified proteins bind to sequences adjacent to the SV40 origin of replication. *Cell*, 65, 1083-1091.

Kern, S.E., Kinzler, K.W., Bruskin, A., Jarosz, D., **Friedman, P.N.**, Prives, C. and Vogelstein, B. 1991. Identification of p53 as a sequence-specific DNA-binding protein. *Science*, 252, 1708-1710.

Farmer, G., Bargonetti, J., Zhu, H., **Friedman, P.N.**, Prywes, R., and Prives, C. 1992. Wild-type p53 activates transcription in vitro. *Nature*, 358, 83-86.

Prives, C., Bargonetti, J., **Friedman, P.N.**, Manfredi, J.J., and Wang, E. 1992. Functional consequences of the interaction between the p53 tumor suppressor protein and the SV40 large tumor antigen. *Cold Spring Harbor Symposium on Quantitative Biology: The Cell Cycle*, Vol. 56, 227-235.

Bargonetti, J., Reynesdottir, I., **Friedman, P.N.**, and Prives, C. 1992. Wild-type p53 site-specific binding to cellular DNA is regulated by SV40 T antigen and mutant p53. *Genes and Devel.*, 6, 1886-1898.

Friedman, P.N., Wang, E.H., Meerovitch, K., Sonenberg, N., and Prives, C. 1992. Murine p53 inhibits the function but not the formation of SV40 T antigen hexamers and stimulates T antigen RNA helicase activity. *Chromosoma*, 102, 60-66.

Friedman, P.N., Chen, X., Bargonetti, J., and Prives, C. The p53 protein is an unusually shaped tetramer that binds directly to DNA. *PNAS*, 90, 3319-3323.

Reynesdottir, I., Lorimer, H.E., Friedman, P.N., Wang, E.H., and Prives, C. 1993. Phosphorylation and active ATP hydrolysis are not required for SV40 T antigen hexamer formation. *J. of Biol. Chem.*, 268, 24647-24654.

Friedman, P.N., McAndrew, S.J., Gawlak, S.L., Chace, D., Trail, P.A., Brown, J.P., and Siegall, C.B. 1993. BR96 sFv-PE40, a potent single-chain immunotoxin that selectively kills carcinoma cells. *Cancer Res.*, 53, 334-339.

Friedman, P.N., Chace, D.F., Trail, P.A., and Siegall, C.B. 1993. Antitumor activity of the single-chain immunotoxin BR96 sFv-PE40 against established breast and lung tumor xenografts. *J. of Immun.*, 150, 3054-3061.

Friedman, P.N., Chace, D.F., Gawlak, S.L., and Siegall, C.B. 1993. The single-chain immunotoxins BR96 sFv-PE40 and BR96 sFv-PE38: Potent anti-tumor agents for the treatment of human cancer. In *Growth Factors, Peptides, and Receptors*, T. Moody, ed., Plenum Press, 409-414.